Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (141-150 of 188) with videos related to

Pageof 19
Sort By:
Plos One|July 15, 2015
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk SarcomasXin Huang, Haein Park, Joseph Greene, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value AnalysisColby J Hyland, Flora Varghese, Christina Yau, et al.
Cancer Research|December 20, 2014
eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cellsSvetlana Avdulov, Jeremy Herrera, Karen Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineAnn H Partridge, R Bryan Rumble, Lisa A Carey, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 15, 2017
A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast CancerHamed Samavat, Giske Ursin, Tim H Emory, et al.
Cancer Causes & Control : CCC|July 25, 2015
The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristicsHamed Samavat, Allison M Dostal, Renwei Wang, et al.
Nature|February 8, 2013
APOBEC3B is an enzymatic source of mutation in breast cancerMichael B Burns, Lela Lackey, Michael A Carpenter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come, Aman U Buzdar, James N Ingle, et al.
Radiology|July 26, 2005
Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 TSina Meisamy, Patrick J Bolan, Eva H Baker, et al.
Science Advances|October 13, 2016
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancerEmily K Law, Anieta M Sieuwerts, Kelly LaPara, et al.
Pageof 19

Showing results (141-150 of 188) with videos related to

Sort By:
Pageof 19
Plos One|July 15, 2015
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk SarcomasXin Huang, Haein Park, Joseph Greene, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value AnalysisColby J Hyland, Flora Varghese, Christina Yau, et al.
Cancer Research|December 20, 2014
eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cellsSvetlana Avdulov, Jeremy Herrera, Karen Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 4, 2014
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineAnn H Partridge, R Bryan Rumble, Lisa A Carey, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 15, 2017
A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast CancerHamed Samavat, Giske Ursin, Tim H Emory, et al.
Cancer Causes & Control : CCC|July 25, 2015
The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristicsHamed Samavat, Allison M Dostal, Renwei Wang, et al.
Nature|February 8, 2013
APOBEC3B is an enzymatic source of mutation in breast cancerMichael B Burns, Lela Lackey, Michael A Carpenter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statementSteven E Come, Aman U Buzdar, James N Ingle, et al.
Radiology|July 26, 2005
Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 TSina Meisamy, Patrick J Bolan, Eva H Baker, et al.
Science Advances|October 13, 2016
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancerEmily K Law, Anieta M Sieuwerts, Kelly LaPara, et al.
Pageof 19